Zometa
Osteoporosis, Chemotherapy, Osteoporosis + 10 more
Treatment
20 Active Studies for Zometa
Treatment for
Osteoporosis
What is Zometa
Zoledronic acid
The Generic name of this drug
Treatment Summary
Zoledronic acid (also known as CGP 42'446) is a medication used to treat and prevent a variety of bone-related conditions, including osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. It was first approved by the FDA in 2001 and is classified as a third-generation, nitrogen-containing bisphosphonate, similar to ibandronic acid, minodronic acid, and risedronic acid.
Zometa
is the brand name
Zometa Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Zometa
Zoledronic acid
2001
53
Effectiveness
How Zometa Affects Patients
Zoledronic acid is a medication used to prevent bone loss that works by blocking the action of osteoclasts. It has a wide range of therapeutic benefits and does not typically cause severe side effects from an overdose. However, it can cause issues such as electrolyte deficiencies, renal impairment, jaw necrosis, fractures, lung constriction, liver damage, low calcium levels, and harm to unborn babies. Patients should be aware of these risks before taking the medication.
How Zometa works in the body
Bisphosphonates work in the body by attaching to bone, which prevents the osteoclasts from breaking down the bone and causes them to detach. This stops the bone from being broken down and resorbed. In addition, nitrogen-containing bisphosphonates like zoledronate also block the mevalonate pathway, which is necessary for certain proteins to function and survive. This causes them to die off, which helps to stop the spread of tumor cells. Finally, zoledronate activates caspases, which also contributes to cell death.
When to interrupt dosage
The proposed amount of Zometa is contingent upon the diagnosed ailment, including Bone Mineral Density, Paget’s Disease and Osteoporosis caused by glucocorticoid. The amount of dosage is subject to the administration procedure featured in the table below.
Condition
Dosage
Administration
Osteoporosis
, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Osteoporosis
, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Bone Metastases
, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Malignant Neoplasms
, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Paget’s Disease
, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Osteoporosis
, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Chemotherapy
, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Multiple Myeloma
, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Osteoporosis
, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Glucocorticoids
, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Disease
, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Postmenopause
, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Osteitis Deformans
, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Warnings
Zometa Contraindications
Condition
Risk Level
Notes
Renal Insufficiency, Chronic
Do Not Combine
Hypocalcemia
Do Not Combine
Acute Kidney Injury
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Zoledronic Acid may interact with Pulse Frequency
There are 10 known major drug interactions with Zometa.
Common Zometa Drug Interactions
Drug Name
Risk Level
Description
Alendronic acid
Minor
The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Alendronic acid.
Clodronic acid
Minor
The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Clodronic acid.
Etidronic acid
Minor
The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Etidronic acid.
Ibandronate
Minor
The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Ibandronate.
Incadronic acid
Minor
The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Incadronic acid.
Zometa Toxicity & Overdose Risk
Overdosing on a drug may cause reduced kidney function, low levels of calcium, phosphorus, and magnesium in the blood. If this occurs, intravenous treatment with the lacking ions is necessary.
Zometa Novel Uses: Which Conditions Have a Clinical Trial Featuring Zometa?
320 active clinical trials are assessing the efficacy of Zometa in providing relief for Osteoporosis, Malignant Neoplasms and Solid Tumors.
Condition
Clinical Trials
Trial Phases
Osteoporosis
3 Actively Recruiting
Not Applicable, Phase 2
Multiple Myeloma
6 Actively Recruiting
Phase 1, Phase 2
Bone Metastases
7 Actively Recruiting
Phase 4, Not Applicable, Phase 2, Phase 3
Disease
1 Actively Recruiting
Not Applicable
Osteoporosis
0 Actively Recruiting
Malignant Neoplasms
0 Actively Recruiting
Chemotherapy
4 Actively Recruiting
Phase 1, Phase 3, Not Applicable
Postmenopause
5 Actively Recruiting
Phase 2, Not Applicable
Glucocorticoids
0 Actively Recruiting
Paget’s Disease
0 Actively Recruiting
Osteoporosis
27 Actively Recruiting
Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2
Osteoporosis
0 Actively Recruiting
Osteitis Deformans
0 Actively Recruiting
Zometa Reviews: What are patients saying about Zometa?
5
Patient Review
10/12/2016
Zometa for Lesions in the Bone of the Disease Multiple Myeloma
5
Patient Review
6/24/2014
Zometa for Cancer that has Spread To the Bone From Solid Tumors
5
Patient Review
1/11/2018
Zometa for Lesions in the Bone of the Disease Multiple Myeloma
4.3
Patient Review
8/29/2020
Zometa for Osteoporosis caused by Anti-Androgen Drugs
4
Patient Review
5/18/2022
Zometa for prevention of skeletal related events in multiple myeloma
3.7
Patient Review
7/13/2014
Zometa for Osteoporosis
2.3
Patient Review
2/7/2017
Zometa for Lesions in the Bone of the Disease Multiple Myeloma
2.3
Patient Review
4/25/2015
Zometa for Increased Calcium in the Blood from Cancer
1.3
Patient Review
7/1/2022
Zometa for Osteoporosis
1
Patient Review
10/2/2020
Zometa for Cancer that has Spread To the Bone From Solid Tumors
1
Patient Review
8/26/2022
Zometa for Osteoporosis
1
Patient Review
1/29/2019
Zometa for Increased Calcium in the Blood from Cancer
1
Patient Review
3/10/2019
Zometa for Cancer that has Spread To the Bone From Solid Tumors
1
Patient Review
10/30/2019
Zometa for Glucocorticoid-Induced Osteoporosis Prevention
1
Patient Review
6/2/2014
Zometa for Cancer that has Spread To the Bone From Solid Tumors
Patient Q&A Section about zometa
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is Zometa chemotherapy?
"Zoledronic acid is not a cancer chemotherapy, however it can be used to treat bone disease in patients who have cancer. Zoledronic acid is in a class of medications called bisphosphonates."
Answered by AI
What does Zometa do to your body?
"This medication works by reducing the amount of calcium that is released from the bones into the bloodstream. It also slows down the rate at which cancer cells break down bones, which helps to prevent fractures."
Answered by AI
What are the long term side effects of Zometa?
"Some possible symptoms of a brain tumor could include changes in vision, decreased frequency of urination, increased tearing, heavy feeling in the jaw, and increased blood pressure."
Answered by AI
Is Zometa cancer treatment?
"The drug Zometa is approved by the FDA to treat multiple myeloma and bone metastases from solid tumors. It is typically used in conjunction with other standard treatments for cancer, such as chemotherapy, radiation therapy, and hormone therapy. Zometa is also sometimes used to treat bone metastases specifically from prostate cancer."
Answered by AI